A Novel Polymeric Trileaflet Heart Valve Prosthesis

Information

  • Research Project
  • 6834375
  • ApplicationId
    6834375
  • Core Project Number
    R43HL078049
  • Full Project Number
    1R43HL078049-01
  • Serial Number
    78049
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/1/2004 - 19 years ago
  • Project End Date
    1/31/2006 - 18 years ago
  • Program Officer Name
    BALDWIN, TIM
  • Budget Start Date
    8/1/2004 - 19 years ago
  • Budget End Date
    1/31/2006 - 18 years ago
  • Fiscal Year
    2004
  • Support Year
    1
  • Suffix
  • Award Notice Date
    6/28/2004 - 19 years ago
Organizations

A Novel Polymeric Trileaflet Heart Valve Prosthesis

DESCRIPTION (provided by applicant): The development of a durable, hemocompatible valve prosthesis is the long-term objective of this proposal. While heart valve prostheses have been used successfully since 1960, 10-year survival rates still range from 37-58%. Existing replacement valves are either mechanical or biological. Bioprostheses suffer from time dependent structural changes leading to valve failure, while mechanical valves are subject to thrombus deposition and subsequent complications resulting from emboli. A valve offering the hemocompatibility of bioprostheses and the durability of mechanical valves would provide a superior alternative to those currently approved for clinical use. ABIOMED's polyurethane trileaflet valve has demonstrated excellent durability and hemocompatibility in clinical evaluation of the AbioCor replacement heart. The goal of this Phase I project is the development of a trileaflet heart valve prosthesis with low trans-valve pressure loss. The proposed work involves adapting the existing 24mm ABIOMED valve design to the requirements of a smaller, 21mm prosthetic valve, which is the most frequently used size in replacement surgeries. This work also includes in vitro performance characterization and accelerated valve cycling, as well as computer simulation using a novel computational fluid dynamics package. In Phase II, the valve design will be optimized, and hemocompatibility will be assessed through in vivo animal experiments.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    99870
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:99870\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ABIOMED, INC.
  • Organization Department
  • Organization DUNS
    050636737
  • Organization City
    DANVERS
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    01923
  • Organization District
    UNITED STATES